Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Clears HIV Oral Antiviral For COVID, Vows More Drug Approvals

Executive Summary

As the Communist Party of China gears up for its once in every five years National Congress late this fall, the need for more novel drugs to help address the persistent coronavirus pandemic is rising amid the country’s strict “COVID Zero” policies.

You may also be interested in...



China Cool On Nasal Vaccines, Backs Antivirals In Latest COVID Guidance

China’s Center for Drug and Evaluation has issued new guidance on the development of new vaccines and drugs for COVID-19 in which it backs antivirals as a key weapon, while the Politburo has shown no signs of backing away from the country's tough "COVID Zero" policies.

Japan Again Postpones Approval Of Shionogi COVID Antiviral

Xocova’s emergency approval stymied by uncertainties over efficacy and other characteristics that could effectively limit its use, prompting decision to await Phase III data later this year.

Brii Launches COVID Antibody As Shanghai Tightens Restrictions

Six months after Brii obtained Chinese approval for its antibody combo for COVID-19, the Beijing joint venture finally launches the drug in China.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel